Trans-activation of heparanase promoter by ETS transcription factors

被引:58
作者
Lu, WC
Liu, YN
Kang, BB
Chen, JH
机构
[1] Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan
[2] Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan
[3] Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan
关键词
ETS; heparanase promoter; tumor metastasis;
D O I
10.1038/sj.onc.1206201
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.
引用
收藏
页码:919 / 923
页数:5
相关论文
共 19 条
[1]   Epithelial mesenchymal interactions in cancer and development [J].
Arias, AM .
CELL, 2001, 105 (04) :425-431
[2]  
BUTTICE G, 1993, J BIOL CHEM, V268, P7196
[3]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[4]  
Chen JH, 1996, ONCOGENE, V13, P1667
[5]   Heparanase, a potential regulator of cell-matrix interactions [J].
Dempsey, LA ;
Brunn, GJ ;
Platt, JL .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (08) :349-351
[6]   Genomic organization and chromosome localization of the newly identified human heparanase gene [J].
Dong, J ;
Kukula, AK ;
Toyoshima, M ;
Nakajima, M .
GENE, 2000, 253 (02) :171-178
[7]   Heparanase: Breaking down barriers in tumors [J].
Eccles, SA .
NATURE MEDICINE, 1999, 5 (07) :735-736
[8]  
FOLKMAN J, 1997, CANC MED, P181
[9]   Human platelet heparanase: purification, characterization and catalytic activity [J].
Freeman, C ;
Parish, CR .
BIOCHEMICAL JOURNAL, 1998, 330 :1341-1350
[10]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70